Palliative chemotherapy during the last month of life

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2375-2380

  Nappa U ^a,b   Lindqvist, O ^b,c,d   Rasmussen, B H ^b   Axelsson, B ^a,b  

^a ÖSTERSUND HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Stockholms Sjukhem Foundation   (Sweden)

Author keywords

Cancer; Chemotherapy; Decision making; Palliative treatment; Retrospective study

Indexed keywords

ALKALOID; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYTOTOXIC AGENT; NATURAL PRODUCT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DEMOGRAPHY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; EPITHELIAL CANCER; FEMALE; GYNECOLOGIC CANCER; HEALTH CARE UTILIZATION; HOME; HOSPITAL ADMISSION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SURVIVAL TIME; SWEDEN; TERMINAL CARE; TREATMENT DURATION; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; SWEDEN; TERMINAL CARE;

EID: 80155174316     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq778     Document Type: Article

References (34)

1. O'Brien MER, Yau T, Coward J et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age >= 70 years) with non-small cell lung cancer. Clin Oncol 2008; 20: 142-147.
2. Kim A, Fall P, Wang D. Palliative care: optimizing quality of life. J Am Osteopath Assoc 2005; 105: S9-S14.
3. Renouf D, Kennecke H, Gill S. Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer 2008; 7: 386-389.
4. Bjordal K, Aass N. Palliativ cytostatikabehandling. Tidsskr Nor Laegeforen 2004; 24: 3206-3207.
5. McIllmurray M. The medical treatment of cancer in palliative care. In Hanks G, Cherny N, Christakis N et al. (eds), Oxford Textbook of Palliative Medicine, 4th edition. New York: Oxford University Press 2010; 513-525.
6. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-656.
7. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
8. Martoni AA, Tanneberger S, Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 2007; 93: 417-422.
9. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
10. Emanuel EJ, Young-Xu Y, Levinsky NG et al. Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med 2003; 138: 639-643.
11. Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006; 11: 1095-1099.
12. Statistics Sweden. Befolkningsstatistik/Folkmä ngd. http://www.scb.se (16 December 2010, date last accessed).
13. WHO Collaborating Centre for Drug Statistics Methodology. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology Antineoplastic Agents. http://www.whocc.no (16 December 2010, date last accessed).
14. Yun YH, Kwak M, Park SM et al. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007; 72: 164-171.
15. Giorgi F, Bascioni R, Brugni M et al. Chemotherapy use at the end of life: an analysis of the decision making process. J Clin Oncol (Meeting Abstracts) 2004; 22: 6081.
16. Kao S, Shafiq J, Vardy J, Adams D. Use of chemotherapy at end of life in oncology patients. Ann Oncol 2009; 20: 1555-1559.
17. Braga S, Miranda A, Fonseca R et al. The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psychooncology 2007; 16: 863-868.
18. Ronis DL, Duffy SA, Fowler KE et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 241-248.
19. Goncxalves J, Goyanes C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer 2008; 16: 321-327.
20. Keam B, Oh D-Y, Lee S-H et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol 2008; 38: 381-386.
21. Earle CC, Neville BA, Landrum MB et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22: 315-321.
22. Asola R, Huhtala H, Holli K. Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 2006; 100: 77-82.
23. Thorne SE, Bultz BD, Baile WF. Is there a cost to poor communication in cancer care?: a critical review of the literature. Psychooncology 2005; 14: 875-884.
24. Lewin SN, Buttin BM, Powell MA et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol 2005; 99: 261-266.
25. Connor SR, Pyenson B, Fitch K et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007; 33: 238-246.
26. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when is enough, enough?" . JAMA 2008; 299: 2667-2678.
27. Hashimoto K, Yonemori K, Katsumata N et al. Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist 2009; 14: 752-759.
28. Wright AA, Zhang B, Ray A et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008; 300: 1665-1673.
29. Wedding U, Ködding D, Pientka L et al. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007; 64: 1-9.
30. Balducci L. Aging, frailty and chemotherapy. Cancer Control 2007; 14: 7-12.
31. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
32. Lord SR, Hall PS, McShane P et al. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clin Oncol 2010; 22: 107-113.
33. Trumper M, Ross PJ, Cunningham D et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006; 42: 827-834.
34. Lichtman SM. Chemotherapy in the elderly. J Aging Health 2007; 3: 165-175.